Medincell Sa Stock Fundamentals
| MDCLF Stock | USD 14.00 7.02 100.57% |
MedinCell SA fundamentals help investors to digest information that contributes to MedinCell's financial success or failures. It also enables traders to predict the movement of MedinCell Pink Sheet. The fundamental analysis module provides a way to measure MedinCell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MedinCell pink sheet.
MedinCell |
MedinCell SA Company Operating Margin Analysis
MedinCell's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current MedinCell Operating Margin | (3.25) % |
Most of MedinCell's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MedinCell SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, MedinCell SA has an Operating Margin of -3.2526%. This is 90.73% lower than that of the Healthcare sector and 97.1% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 40.97% lower than that of the firm.
MedinCell SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MedinCell's current stock value. Our valuation model uses many indicators to compare MedinCell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MedinCell competition to find correlations between indicators driving MedinCell's intrinsic value. More Info.MedinCell SA is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MedinCell's earnings, one of the primary drivers of an investment's value.MedinCell Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedinCell's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MedinCell could also be used in its relative valuation, which is a method of valuing MedinCell by comparing valuation metrics of similar companies.MedinCell is currently under evaluation in operating margin category among its peers.
MedinCell Fundamentals
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 190.33 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.61 % | |||
| Shares Owned By Institutions | 19.00 % | |||
| Price To Book | 34.52 X | |||
| Price To Sales | 31.58 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Net Income | (24.81 M) | |||
| Cash And Equivalents | 34.39 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.86 % | |||
| Current Ratio | 2.84 X | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (0.88) X | |||
| Number Of Employees | 151 | |||
| Beta | 1.02 | |||
| Market Capitalization | 244.65 M | |||
| Total Asset | 44.3 M | |||
| Z Score | 9.0 | |||
| Net Asset | 44.3 M |
About MedinCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedinCell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedinCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedinCell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. Medincell is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.